Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Pre-Symptomatic Study of Intravenous Onasemnogene Abeparvovec-xioi in Spinal Muscular Atrophy (SMA) for Patients With Multiple Copies of SMN2 (SPR1NT)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03505099
Recruitment Status : Completed
First Posted : April 23, 2018
Last Update Posted : July 29, 2021
Sponsor:
Collaborator:
PRA Health Sciences
Information provided by (Responsible Party):
Novartis ( Novartis Gene Therapies )

No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : Completed
Actual Primary Completion Date : June 15, 2021
Actual Study Completion Date : July 15, 2021